Member Info for Filter29

We have 2 potential wins still in Q1, Oxilio & successful with the innovate grant application.

Agree with others that everything seems to point to Oxilio being a winner, I really hope so, more money in the bank and some regular revenue up to £2m a yr really would speed things up. And the grant and we are in a much better place going forward.

It's been a frustrating time here but we have more transparency with Anne and I really think she'll turn our fortunes here.

Has had some updates after RNS

Trying to see positives short term, the volume is huge today, I know the twitter rampers are all over this today but if we're flushing out AC/DT the time that can only be good news in the short term for a recovery on next news which could potentially be Oxilio. Looks like NXP001 is our hope for imminent deals and revenue ATM.

It is interesting but then they would say that wouldn't they, when NFX can prove they can make a deal and get paid I'd believe it.

As expected new Strategy is basically the same as the old one, give me strength.

The director purchases are a bit pathetic, I hold much more so I have more faith than they do

On the plus side there simply must be an interview today to explain everything in that RNS and reassure shareholders who are being absolutely slammed for having faith here

Was saying they were dead, Jay sweated blind the opposite

Well there we go, who said there was absolutely no need for a placing?????

Someone is loving these cheap shares, pleeeease can we have a buyer TR1'd

Now I've had a word with myself I'm fine with the selling, I do have 2 issues though, a muted SP on news as heavily sold into and not reaching it's potential and 'if' there was any raise coming for NXP002 it'll hurt us long term pi's

True, I'm holding onto any hope that any SP rise on news won't get completely smashed back down by those 2

It is frustrating, we just don't have the volume at the moment for them to sell any quicker. As some have said fingers crossed the next news will be substantial enough for them to change tact and hold

Happy to see this, once the volume increases significantly from here what's left for DT/AC should be cleared.

Changed my tune re: news, I'd be happy for news to land on the 31st March now, if they're going to sell at least 1m between them by then we'd be in a better place without being held back too much.

The Twitter is terrible, can't someone take up the reigns and just share company news, research, news in relevant areas we're involved in. I know it's a small company but it's not hard is it. That's if it is them, could've been a pi settting it up

Someone is still happy to pick up shares in bulk, they'll be laughing once things kick on here

It's crazy, just need the market to cotton on

All sounds great but we'll need to wait and see if we can finally see some deals and regular revenue coming in.

Looks like someone wants out asap, AC at a guess, hurry up and sell on near the 52 week low, your loss in the long run

Definitely Chab, gives me hope this is the very bottom which makes this large seller seem very silly (unless they absolutely need the funds asap of course). Investing down here near 2.5p is a pretty safe bet in my opinion

Someone's loading up on cheap shares.

Have everything crossed next week is good to us, so much possible news flow volume should clear seller/s pretty quickly I'd hope, as said if it's great news they'll think more about holding what's left. Anything Covid related will get ramped to high heaven on Twitter which should provide great liquidity.

That's my thinking and why I've brought more, I just know Anne is going to start delivering, to mess it up even more is unthinkable.

I annoy myself by looking at the SP all the time, there's no need as I'm investing not trading, I just know the potential and can't wait to see it reflected in my portfolio

You wouldn't think the strategy would change too much from the current one below, hopefully we have an update where everything is individually........

Our business model is one with very low operating costs, but we diversify the means by which revenues are derived. Our strategy therefore takes three approaches, each underpinning a balance of risk and reward and timing of returns and revenue generation. We will:

Undertake technology licensing agreements centred on our IP and provide fee-for-service work to third parties producing their proprietary products, providing Nuformix with short-term revenue streams.

Apply Nuformix’s IP to produce our own proprietary product opportunities for short-term development and out-licensing, providing potentially larger, medium-term revenue streams.

Evaluate co-development opportunities, with third parties, of generic products where Nuformix’s IP provides renewed patent protection, allowing access to more rapid development to market and risk-share appropriate for Nuformix.